Securing Sales Network
Samsung Bioepis is said to be reviewing the acquisition of the biosimilar business unit of U.S. biotech firm Biogen.
According to the biotech industry on Aug. 2, Samsung Bioepis is considering acquiring Biogen’s biosimilar business unit, which has recently been put up for sale.
Biogen has been a collaborative partner for Samsung Bioepis in selling its biosimilar products overseas and announced earlier this year that it will be selling its biosimilar business unit.
Industry insiders predict that if the acquisition indeed takes place, it will have a positive impact on product sales, as Samsung Bioepis can directly secure a sales network within the U.S.
However, a Samsung Bioepis official stated that no final decisions have been made yet.
Jasmine Choi
pr@businesskorea.co.kr